Compare LC & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | IRON |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2008 | 2020 |
| Metric | LC | IRON |
|---|---|---|
| Price | $14.61 | $65.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $22.67 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 1.8M | 997.1K |
| Earning Date | 04-27-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.78 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $314,702,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | $101.57 |
| P/E Ratio | $12.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $30.82 |
| 52 Week High | $21.67 | $99.50 |
| Indicator | LC | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 46.47 |
| Support Level | $12.25 | $57.45 |
| Resistance Level | $17.41 | $69.36 |
| Average True Range (ATR) | 0.85 | 3.10 |
| MACD | 0.02 | 0.37 |
| Stochastic Oscillator | 21.68 | 66.05 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.